CORELLATION BRANCHED CHAIN AMINO ACID IN INHIBITING THE PROGRESSIVITY OF CHRONIC KIDNEY DISEASE STAGE 2-4 IN CHILDREN

esthy poespitaningtyas, Roedi Irawan, Ninik Asmaningsih Soemyarso, Jusak Nugraha

Abstract


Chronic kidney disease (CKD) is not uncommon issue in children. CKD is the abnormality of structure or function of the kidney that occurs for more than 3 months. Progresivity of CKD characterized by the presence of longitudinal decline in Glomerulus Filtration Rate (GFR), proteinuria and hypertension. One of the recommendations of the prevention of nutritional supplementation in CKD by administering oral Branched Chain Amino Acid (BCAA). Recently, there has been no research to figure the effects of the of BCAA on children with CKD stage 2-4. Randomized pre-post test controlled trial study was conducted in Nephrology pediatric outpatient clinic Dr. Soetomo hospital with CKD stage 2-4, divided into 2 groups, the BCAA and placebo, followed for 8 weeks to be evaluated for GFR, albumin, proteinuria, blood pressure and nutritional status. Sixteen children with CKD stage 2-4 were enrolled in this study, 71.4% of patients were boys. The mean age was 12.5 (SD 2.90) years. CKD stage 2 about 50% (p=0,767). Nephrotic syndrome was the most common underlying cause of CKD (p=0,149). Moderate malnutrition was about 50% (p=1,000) and short stature was 64.28% (p=1.000). In BCAA group there was decrease of GFR -5.08±7,13 (p=0.055), increase of albumin serum 0.20±0.23 (p=0,062), decrease of delta systole -11,57±15.08 (p=0,565) and diastole -4,85±16.25 (p=0,708), weight loss -0.07±1.01 (p=0.828), an increase of height 0.14±0.24 (p=0,771), and a decrease in BMI -0.03±0.74 (p=0,389). The conclusion in this study is Branched chain amino acid (Leucine, Isoleucine and Valine) supplementation did not provide significant effect in inhibiting progresivity of CKD stage 2-4 in children and improvement of nutritional status.


Keywords


Chronic kidney disease, Branched chain amino acid, progresivity of CKD, nutritional status.

References


REFERENCES

KDOQI. Clinical practice guideline for nutrition in children with chronic kidney disease. Am J Kidney Dis. 2002; 39(1): S1-S26.

Hogg RJ. National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative Clinical Practice Guidelines for Chronic Kidney Disease in Children and Adolescents: Evaluation, Classification, and Stratification. Pediatrics. 2003; 111: 1416-21

Levey AS. Chronic Kidney Disease Progression. Lancet. 2007; 379: 165-80.

Hammarqvist F, Wernerman J, Ali R, von der Decken A, and Vinnars E. Addition of glutamine to total parenteral nutrition after elective abdominal surgery spares free glutamine in muscle, counteracts the fall in muscle protein synthesis, and improves nitrogen balance. Annals of Surgery. 1989; 209(4): 455-61.

Nair KS and Short KR. Hormonal and signaling role of branched-chain amino acids. J of Nutr. 2005; 135(6): 1547S-52S.

Hiroshige K, Sonta T, Suda T, Kanegae K, and Ohtani A. Oral supplementation of branched-chain amino acid improves nutritional status in elderly patients on chronic haemodialysis. Nephrol Dial Transpl. 2001; 16(9): 1856-62.

Schuldt S, Carter P, and Welbourne T. Glutamate transport asymmetry and metabolism in the functioning kidney. Am J of Physiol Endocr and Metab. 1999; 277(3): E439-46.

Khan IA, Nasiruddin M, Haque SF and Khan RA. A Randomized clinical trial to evaluate the efficacy and safety of a-keto amino acids in stage 3 and 4 of Chronic Kidney Disease. Asian J Pharm Clin Res. 2014; 7(3): 21-4.

Soares CMB, Diniz JSS, Lima EM, Silva JMP, Oliveira GR and Canhestro MR, et al. Clinical outcome of children with chronic kidney disease in a pre-dialysis interdisciplinary program. Pediatr Nephrol. 2008; 23: 2039-46.

Ardissino G, Daccò V and Testa S, et al. Epidemiology of chronic renal failure in children: data from the ItalKid project. Pediatrics. 2003; 111: e382–7.

Warady BA and Chadha V. Chronic kidney disease in children: the global perspective. Pediatr Nephrol. 2007; 22: 1999-2009.

Amira P, Bogdanovic R, Paripovic D, Paripovic A, Kocev N, Golubovic and Milosevic B. Epidemiology of chronic kidney disease in children in Serbia. Nephrol Dial Transplant. 2011; 27: 1978-84.

Stel VS, Kramer A and Zoccali C, et al. The 2007 ERA-EDTA registry annual report-a precis. NDT plus. 2009; 2: 514-52.

Gheissari A, Hemmatzadeh S, Merrikhi A, Tehrani SF and Madihi Y. Chronic Kidney disease in children: a report from a tertiary care centre over 11 years. J Nephropathol. 2012; 1: 177-82.

Wong H, Mylrea K, Feber J, Drukker A and Filler G. Prevalence of complication in children with chronic kidney disease according to KDOQI. Kidney Int. 2006; 70: 585-90.

Wilson LM. Sindrom Uremik. In: Price SA, Wilson LM (eds). Clinical Concept of Disease Processes, 4th ed. EGC, Jakarta. 1995; 848-61.

Cano NJ, Fouque D and Leverve XM. Application of branched chain amino acids in human pathological states: renal failure. J Nutr. 2006; 136: 299S–307S.

Grahammer F, Wanner N and Huber TB. mTOR controls kidney epithelia in health and disease. Nephrol Dial Transplant. 2014; 29: 109-18.

Huber TB, Walz G and Kuehn EW. mTOR and rapamycin in the kid¬ney: signaling and therapeutic implications beyond immunosup¬pression. Kidney Int. 2011; 79: 502-11.

Hay N and Sonenberg N. Upstream and downstream of mTOR. Genes and Development. 2004; 18(16): 1926–45.

Ijichi C, Matsumura T, Tsuji T and Eto Y. Branched-chain amino acids promote albumin synthesis in rat primary hepatocytes through the mTOR signal transduction system. Biochem Bioph Res Co. 2003; 303(1): 59–64.

Bellizzi V, Di lorio BR, and De Nicola L, et al. Very low protein diet supplemented with ketoanalogs improves blood pressure control in chronic kidney disease. Kid Int. 2007; 71: 245-51.

McAllan L, Cotter PD, Roche HM, Korpela R and Nilaweera KN. Impact of leucine on energy balance. J Physiol Biochem. 2013; 69: 155–63

Chazot C. Why are chronic kidney disease patients anorexic and what can be done about it?. Seminars in Nephrol. 2008; 29(1): 15-23.

Walser M, Coulter W, Dighe S and Crantz FR. The effect of ketoanalogues of essential amino acids in severe chronic uremia. J Clin Invest. 1973; 52: 678-90.

Mitch WE, Price SR, May RC, Jurkovitz C and England BK. Metabolic consequences of uremia: extending the concept of adaptive responses to protein metabolism. Am J Kidney Dis. 1994; 23: 224-8.

Meng WC, Leung KL, Ho RL, Leung TW and Lau WY. Prospective randomized control study on the effect of branched-chain amino acids in patients with liver resection for hepatocellular carcinoma. Aust N Z J Surg. 2014; 69: 811–5.




DOI: http://dx.doi.org/10.24293/ijcpml.v26i2.1467

Refbacks

  • There are currently no refbacks.